GlobalData predicts that tirzepatide is likely to be increasingly prescribed for broader cardiometabolic disease.

KOLKATA: The National Pharmaceutical Pricing Authority (NPPA) revised prices for 80 medicines from April 1, with major cuts ...

Kolkata: The National Pharmaceutical Pricing Authority (NPPA), in an order dated March 27, changed the prices of 80 medicines ...

The National Pharmaceutical Pricing Authority (NPPA) has fixed prices of 80 new drugs including anti-diabetes, anti-hypertension, pain relief formulations from major pharmaceutical companies, in its ...

Revenues of €9.2 million for the full year of 2024Cash and cash equivalents at €96.6 million as of December 31, 2024 First ...

In March 2025, Shandong Suncadia Medicine Co., Ltd. conducted a phase II Clinical Study of Efficacy and Safety of HRS-1780 ...

India is home to more than 100 million diabetics, and the demand for anti-diabetic drugs is on the rise -- the Rs 20,611 ...

USV launches empagliflozin and its combinations for diabetes care in India: Our Bureau, Bengaluru Wednesday, March 19, 2025, 12:40 Hrs [IST] USV, an Indian multinational healthcar ...

Morepen Laboratories Limited announces the launch of Empamore, a game-changing treatment for Type 2 Diabetes Mellitus, Heart Failure with Reduced Ejection Fraction, and Chronic Kidney Disease.

The uptick in the Morepen Labs share came after the company announced that it has rolled out ‘Empamore.’ Empamore is used to ...

Morepen Laboratories surged 8.90% to Rs 46.61 after the company launched Empamore, an affordable treatment for type 2 diabetes, heart failure, and chronic kidney disease in India.

Are you ignoring the early signs of kidney disease in diabetes? As diabetic kidney disease is on the rise, here’s what doctors want you to know!